Ophthalmology Drugs Global Market Report 2022 – Yahoo Finance
Kevin Heal and Stephen Bigger break down potential benefits of rate hikes on financial stocks Wed, March 9 at 2 p.m. ET.
Major companies in the ophthalmology drugs market include Regeneron Pharmaceuticals, Inc. , Novartis AG, AbbVie, Santen Pharmaceutical Co. , F. Hoffmann-La Roche Ltd. , Bausch Health Companies Inc. , Bayer AG, Sumitomo Chemical Co.
New York, March 04, 2022 (GLOBE NEWSWIRE) — Reportlinker.com announces the release of the report "Ophthalmology Drugs Global Market Report 2022" – https://www.reportlinker.com/p06241979/?utm_source=GNW
ltd., Mitsubishi Tanabe Pharma Corporation and Horizon Therapeutics plc.
The global ophthalmology drugs market is expected to grow from $50.62 billion in 2020 to $56.07 billion in 2021 at a compound annual growth rate (CAGR) of 10.8%. The growth is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $80.10 billion in 2025 at a CAGR of 9.3%.
The ophthalmology drugs market consists of sales of ophthalmology drugs and related services by entities (organizations, sole traders and partnerships) that produce ophthalmology drugs to treat eye related diseases.The ophthalmology drugs industry includes establishments that produce pharmaceutical drugs to treat glaucoma diseases, anti- inflammatory and tear stimulating drugs under dry eye medications drugs, and other drugs for treating retinal disorders and allergies.
Some of the major ophthalmic drugs include Eylea, Lucentis, Restasis, Vigamox, Azopt, and Lotemax.
The main types of ophthalmology drugs are antiglaucoma drugs, dry eye medication, and other ophthalmological drugs (retinal disorders, anti-infectives/allergy).Anti-glaucoma drugs are medications used to prevent or treat glaucoma, which is a disease in which the optic nerve is damaged, resulting in progressive, irreversible vision loss.
The different types include pharmaceutical drugs, and biologics.The drugs are administered through oral, parenteral, and others that are classified into branded and generic drugs.
The various mode of purchase includes prescription-based drugs and over-the-counter drugs which are distributed by hospital pharmacies, retail pharmacies/ drug stores and others.
North America was the largest region in the ophthalmology drugs market in 2021.Middle East is expected to be the fastest growing region in the forecast period.
The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The expected rise in eye laser surgeries will contribute to the ophthalmology drugs market.Ophthalmology research has proved a link between laser eye surgeries and the prevalence of dry eye disorders.
In an eye laser procedure, cutting of some nerves in the cornea leads to reduction in corneal sensitivity, in response to which, eyes may not sense the need for lubrication, causing the body to produce fewer tears.Dry eye is a common side effect after laser vision correction surgeries.
It is estimated that almost half of the patients that undergo a laser surgery experience some degree of dry eye condition following the procedure.The number of eye laser procedures rose to 720,000 a year in 2020.
A rising number of people going for laser eye surgeries is expected to increase the demand for dry eye medications in the forecast period driving the ophthalmology drugs market.
Regulatory changes are likely to lead to increased costs relating to new product development and service offerings to clients.These changes are related to data protection such as the European Union’s General Data Protection Regulation (GDPR), changes to drug approval procedures and other regulatory changes.
For instance, according to a study on 100 Data Privacy and Data Security statistics for 2020, GDPR compliance is a top priority for 58% of European companies.The GDPR regulation is a EU law on data protection and privacy of individuals residing the European Union and the European Economic Area (EEA).
It also regulates data anonymization thus maintaining integrity of data dealing with patients and other clinical trial studies. The potential loss of revenue due to delays in product release and additional costs incurred due to stringent approval processes puts strain to investments relating to new product development, thereby affecting the growth of the ophthalmology drugs market.
Drug manufacturers are increasingly developing ophthalmic drugs with anti-inflammatory agents to ease patient treatment for dry eye syndrome.Anti-inflammatory drugs are widely used for the treatment of the inflammation produced by the dry eye syndrome, with the topical corticosteroid drops being the most common therapy.
Corticosteroids can rapidly and effectively relieve the symptoms and signs of moderate or severe dry eye.However, prolonged usage of corticosteroids has seen to produce side effects that include risk of bacterial or fungal infection, elevated intraocular pressure and cataract formation.
As a consequence, NSAIDs are increasingly being used as dry eye treatment instead of steroids to minimize the side effects. For instance, Aciex Therapeutics, a US-based pharmaceutical company, is developing NSAIDs which decrease ocular discomfort.
The countries covered in the ophthalmology drugs market report are Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Czech Republic, Denmark, Egypt, Finland, France, Germany, Hong Kong, India, Indonesia, Ireland, Israel, Italy, Japan, Malaysia, Mexico, Netherlands, New Zealand, Nigeria, Norway, Peru, Philippines, Poland, Portugal, Romania, Russia, Saudi Arabia, Singapore, South Africa, South Korea, Spain, Sweden, Switzerland, Thailand, Turkey, UAE, UK, USA, Venezuela and Vietnam.
Read the full report: https://www.reportlinker.com/p06241979/?utm_source=GNW
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need – instantly, in one place.
It's not news that Moderna (NASDAQ: MRNA) and Pfizer (NYSE: PFE) are the undisputed winners of the race to develop and commercialize a coronavirus vaccine. Pfizer expects to make around $32 billion this year from sales of Comirnaty, whereas Moderna expects roughly $19 billion from sales of Spikevax. As great as the jabs from Pfizer and Moderna are at preventing severe disease, they falter when it comes to preventing people from falling ill and being able to infect others.
The idea of paying $5 a gallon for gas scares most Americans — at least the ones who don't live in California, where AAA reports that the price per gallon for gas currently sits at $5.07. "Because the cost of crude oil accounts for about 52% of retail gasoline's final cost, the price of gasoline generally follows movements in crude oil prices, which followed a similar price path during 2019." Crude oil prices have, of course, been rising and they could climb even higher due to Russia's invasion of Ukraine.
Shell PLC has snapped up a cargo of Russian crude at a bargain price, ending a [self-imposed embargo on Russian oil by the international energy industry](https://www.wsj.com/articles/russia-scrambles-to-maintain-oil-sales-life-blood-of-economy-11646156655). Shell bought 100,000 metric tons of Russia’s flagship Urals crude on Friday, according to people familiar with the transaction. It paid $28.50 a barrel below the price of international benchmark Brent crude, the widest discount on record. Lon
(Bloomberg) — After taking a barrage of criticism for buying a cargo of Russian crude, Europe’s largest oil company Shell Plc says it’s navigating the market with government guidance.Most Read from BloombergUkraine Update: Visa, MasterCard Suspend Operations in RussiaUkraine Update: UN Council to Meet, Safety Corridors Set UpPutin Warns Ukraine as Safe-Passage Plans Descend Into ChaosRussia Energy Chaos Triggers the Biggest Market Shock in DecadesRussian Forces Occupy Site of Nuclear Plant as F
The U.S. FDA refused to grant Emergency Use Authorization for COVID-19 vaccine Covaxin in immunizing kids.
Patrick Bafuma is bullish on Legend Biotech (NASDAQ: LEGN) and thinks it might be worth $55 billion by 2027. George Budwell believes his pick, Heron Therapeutics (NASDAQ: HRTX), could jump 1,000% in that time frame. Patrick Bafuma (Legend Biotech): Lost amid the recent market doldrums has been some incredible news.
(Bloomberg) — The chorus is growing from America’s oil executives for President Joe Biden to throw the federal government’s weight behind an industry he once deliberately shunned: U.S. shale.Most Read from BloombergRussian Forces Occupy Site of Nuclear Plant as Fire ContainedUkraine Update: Russian Troops Occupy Nuclear Plant SiteUkraine Update: Russia Blocks Facebook as Media Crackdown WidensRussia’s Rating Cut to Junk; Talks on Tap: Ukraine UpdateWall Street Is Pouncing on Russia’s Cheap Corp
Americans are calling for the boycott of some of Russia's best-known exports in a show of solidarity with Ukraine.
Ocugen's stock price plunged Friday after the Food and Drug Administration declined to issue an emergency use authorization for the Malvern biopharmaceutical company's Covid-19 vaccine. In November, Ocugen (NASDAQ: OCGN) filed an application seeking the emergency use authorization for Covaxin to prevent Covid-19 in children ages 2 to 18. Covaxin is a Covid vaccine developed by Bharat Biotech of India.
China summoned some key rare earths companies amid continuously-rising product prices and urged them to ensure a steady supply chain to help cool prices, the regulator said on Friday. The Ministry of Industry and Information Technology said in a statement that it had instructed producers including China Rare Earth Group, China Northern Rare Earth Group and Shenghe Resources to regulate their operation and trading, and to prevent any market speculation or hoarding. The authority also urged the companies to take a lead in promoting a pricing mechanism for rare earths products and jointly bring prices back to a reasonable range, it said.
Silver prices move higher amid growing supply concerns over precious metals.
"We don't know what exactly is going on," Jenna Jameson tells her followers.
So says a veteran petro market pro, who spies a bubble about to burst. How to use options to protect your position.
BEIJING (Reuters) -The condition of China's winter wheat crop could be the "worst in history", the agriculture minister said on Saturday, raising concerns about grain supplies in the world's biggest wheat consumer. Speaking to reporters on the sidelines of the country's annual parliament meeting, Minister of Agriculture and Rural Affairs Tang Renjian said that rare heavy rainfall last year delayed the planting of about one-third of the normal wheat acreage. A survey of the winter wheat crop taken before the start of winter found that the amount of first- and second-grade crop was down by more than 20 percentage points, Tang said.
(Bloomberg) — Elon Musk says more fossil fuel production is needed now, even if it’s bad for his electric car company, Tesla Inc. Most Read from BloombergUkraine Update: Visa, MasterCard Suspend Operations in RussiaUkraine Update: UN Council to Meet, Safety Corridors Set UpPutin Warns Ukraine as Safe-Passage Plans Descend Into ChaosRussia Energy Chaos Triggers the Biggest Market Shock in DecadesRussian Forces Occupy Site of Nuclear Plant as Fire Contained“Hate to say it, but we need to increase
Petroleo Brasileiro SA chairman Admiral Eduardo Bacellar Leal Ferreira told Reuters on Saturday he plans to step down from the position, with oil executive Rodolfo Landim seen as his possible successor, according to two sources familiar with the matter. "Petrobras chairman is a 24-hour job and I want to spend more time with my family," Ferreira said, adding he has two grown children living outside of Brazil. Ferreira declined to comment further.
A new study found that baricitinib, a rheumatoid arthritis drug developed by Eli Lilly & Co. and Incyte Corp. , reduced the risk of death among patients who have been hospitalized with severe COVID-19. The new
The U.S. and its allies haven't aimed sanctions at Russia's energy exports yet, but buyers are already shying away from the country's crude even as prices soar.
Electric vehicle (EV) maker Rivian reversed course on a price increase yesterday (March 3) that would have charged customers 20% more than the amount originally listed for their cars. In a letter to customers, Rivian CEO RJ Scaringe said the decision ” broke the trust we have worked to build with you,” and that the original price will be honored on Rivian pre-orders made before March 1. The electric truck and SUV maker first began taking pre-orders for its cars in 2018, and soon after, gained financial support from major backers including Amazon, which is waiting on an order of 100,000 Rivian electric delivery vans.
Paypal has suspended its services in Russia following pressure from the Ukrainian government.